NCT02993055已完成1 期
A Phase I, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ulimorelin (LP101)
Lyric Pharmaceuticals0 个研究点目标入组 39 人开始时间: 2015年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 39
- 主要终点
- Measuring the Cmax after administration of Ulimorelin
研究概览
简要总结
A Phase I dose escalation study involving healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- •Subject has clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator at screening or admission as determined by the investigator
- •Subject has abnormal and clinically significant 12-lead ECG at screening or on admission to the clinical study unit at each period
- •Subject has 12-lead ECG demonstrating QTcF >450 msec in males and >470 msec in females at screening. If QTcF exceeds these limits, the ECG should be repeated 2 more times at least 1 minute apart, and the average of the 3 QTcF values should be used to determine the subject's eligibility
- •Subject has a known serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
- •Subjects who are study site employees, or immediate family members of a study site or sponsor employee
- •Subject has supine blood pressure or pulse rate outside of the ranges 90 to 140 mmHg systolic blood pressure/40 to 90 mmHg diastolic blood pressure and 50 to 90 bpm, respectively, at screening or admission or a heart rate below 46 bpm at pre-dose on Day 1 of either the SAD or MAD phase
- •Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
- •Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 2 g per day paracetamol) or herbal remedies in the 7 days before IMP administration
- •Subject has received a vaccine within 30 days before first dosing
- •Subject has a history of drug or alcohol abuse within the past 2 years before screening or a positive result for alcohol at screening or admission
- •Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = 1⁄2 pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
- •Positive drugs of abuse test result
- •Subject has a history of any clinically significant neurological, GI (especially prior gastric or oesophageal surgery, gastroparesis, peptic ulceration, GI bleeding, ulcerative colitis, Crohn's Disease or Irritable Bowel Syndrome), renal, hepatic, pulmonary, metabolic, cardiovascular, psychiatric, endocrine (diabetes mellitus), respiratory or haematological disorder or disease or any other medical condition that, in the opinion of the investigator, would preclude participation in the study
- •Subject has participated in another investigational study within the past 3 months before study drug administration, or subject has previously participated in a study with ulimorelin
- •Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active
- •Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
- •Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study
- •Donation or loss of greater than 400 mL of blood within the previous 3 months
- •History of upper GI surgery
- •Acute diarrhoea or constipation in the 7 days before the predicted first study day. If screening occurs >7 days before the first study day, this criterion will be determined on first study day. Diarrhoea will be defined as the passage of liquid faeces and/or a stool frequency of greater than 3 times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day
- •Subject has any other condition that in the opinion of the investigator precludes participation in the trial
研究组 & 干预措施
Ulimorelin
Experimental
Active
干预措施: Ulimorelin (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Other)
结局指标
主要结局
Measuring the Cmax after administration of Ulimorelin
时间窗: 7 days
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Phase 1 Study of ELX-02 in Healthy Adult SubjectsNonsense MutationGenetic DiseaseNCT03309605Eloxx Pharmaceuticals, Inc.62
撤回
1 期
Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult VolunteersCOVID 19NCT04561076Hengenix Biotech Inc
已完成
1 期
Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy AdultsMEDI3902 for Prevention of P. Aeruginosa PneumoniaNCT02255760MedImmune LLC56
Unknown
1 期
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy SubjectsOveractive BladderNCT02821312Dong-A ST Co., Ltd.110
已完成
1 期
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy SubjectsHealthy SubjectsNCT04788017Shanghai Ark Biopharmaceutical Co., Ltd.24